Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000733308 | SCV000861356 | likely pathogenic | not provided | 2018-05-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005021140 | SCV005651556 | likely pathogenic | Bilirubin, serum level of, quantitative trait locus 1; Crigler-Najjar syndrome type 1; Lucey-Driscoll syndrome; Crigler-Najjar syndrome, type II; Gilbert syndrome | 2024-01-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004737991 | SCV005362344 | likely pathogenic | UGT1A1-related disorder | 2024-08-07 | no assertion criteria provided | clinical testing | The UGT1A1 c.1160_1161delinsGT variant is predicted to result in an in-frame deletion and insertion. This variant in the homozygous or compound heterozygous state has been reported in patients with Crigler-Najjar Syndrome. In vitro experiments showed that the UGT1A1 protein with p.Pro387Arg substitution had residual activity at pH 7.6 but was fully inactive at pH 6.4 (Ciotti et al. 1997. PubMed ID: 9028453). Additionally, other substitutions at the same amino acid (p.Pro387Ser and p.Pro387His) have also been associated with Crigler-Najjar Syndrome (Servedio et al. 2005. PubMed ID: 15712364; Sneitz et al. 2010. PubMed ID: 19830808). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as likely pathogenic. |